Maps (MAPS) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
15 Jul, 2025Executive summary
Achieved double-digit revenue growth for the seventh consecutive semester, with 1H 2024 revenues up 12.6% year-over-year to €14.7 million.
Gross margin improved to 52% in 1H 2024 from 44% in 1H 2023, and EBITDA rose 57.3% to €3.2 million.
Net profit increased to €0.6 million in 1H 2024 from €0.36 million in 1H 2023.
Healthcare segment accounts for more than half of revenues and has regained strong profitability.
Net financial position improved to €7.9 million from €12.5 million at year-end 2023.
Financial highlights
1H 2024 total revenues: €14.7 million, up from €13.1 million in 1H 2023.
EBITDA margin rose to 22% from 15% year-over-year.
Operating cash flow increased 34.5% to €4.4 million in 1H 2024.
CAPEX decreased to €1.4 million from €2.2 million year-over-year.
Shareholders' equity increased to €24.6 million from €22.3 million at end-2023.
Outlook and guidance
Plans to increase market penetration in southern Italy and expand internationally, especially in energy community management software.
Management expects continued growth in 2024 and beyond, supported by sector trends and strategic investments.
Analyst consensus forecasts significant upside, with an average target price of €4.86 and average upside of 93%.
Market consensus expects continued revenue growth, reaching €39.3 million by 2027.
Positive impact anticipated from national energy transition and healthcare digitalization initiatives.
Latest events from Maps
- Healthcare-led product growth and Ellysse acquisition drive strategy amid margin pressure.MAPS
H1 202524 Sep 2025 - Digital transformation in healthcare and energy drives robust growth and strong future outlook.MAPS
Investor Presentation15 Jul 2025 - 2024 saw record profitability, strong product-driven growth, and a robust outlook to 2027.MAPS
Investor Presentation15 Jul 2025 - Record profitability and product-driven growth position the group for further expansion.MAPS
Investor Presentation15 Jul 2025 - Record profitability and cash flow growth driven by scalable products and healthcare strength.MAPS
H2 202415 Jul 2025